MedPath

Sight Sciences

Sight Sciences logo
🇺🇸United States
Ownership
Public
Established
2011-01-01
Employees
214
Market Cap
-
Website
http://www.sightsciences.com
Introduction

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Clinical Trials

16

Active:1
Completed:3

Trial Phases

2 Phases

Phase 4:1
Not Applicable:13

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Not Applicable
13 (92.9%)
Phase 4
1 (7.1%)

OMNI 3.0 Surgical System in Subjects With Primary Open-Angle Glaucoma

Not Applicable
Not yet recruiting
Conditions
Primary Open Angle Glaucoma
First Posted Date
2025-05-27
Last Posted Date
2025-07-01
Lead Sponsor
Sight Sciences, Inc.
Target Recruit Count
25
Registration Number
NCT06991270
Locations
🇵🇦

Panama Eye Center, Panama City, Panama

A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)

Not Applicable
Recruiting
Conditions
Primary Open Angle Glaucoma
Cataract
First Posted Date
2025-04-29
Last Posted Date
2025-07-16
Lead Sponsor
Sight Sciences, Inc.
Target Recruit Count
25
Registration Number
NCT06948773
Locations
🇵🇦

Panama Eye Center, Panama City, Panama

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

Phase 4
Terminated
Conditions
Primary Open Angle Glaucoma
Interventions
First Posted Date
2024-05-09
Last Posted Date
2025-01-29
Lead Sponsor
Sight Sciences, Inc.
Target Recruit Count
2
Registration Number
NCT06407973
Locations
🇺🇸

North Bay Eye Associates, Petaluma, California, United States

🇺🇸

University Eye Specialists, Maryville, Tennessee, United States

A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

Completed
Conditions
Glaucoma, Open-Angle
First Posted Date
2021-09-16
Last Posted Date
2025-01-22
Lead Sponsor
Sight Sciences, Inc.
Target Recruit Count
70
Registration Number
NCT05044793
Locations
🇺🇸

Grene Vision Group, Wichita, Kansas, United States

🇺🇸

Oklahoma Eye Surgeons, Oklahoma City, Oklahoma, United States

🇺🇸

Northern Ophthalmics, Jenkintown, Pennsylvania, United States

and more 1 locations

An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

Completed
Conditions
Glaucoma, Open-Angle
First Posted Date
2021-05-04
Last Posted Date
2025-05-22
Lead Sponsor
Sight Sciences, Inc.
Target Recruit Count
28
Registration Number
NCT04872348
Locations
🇺🇸

Eye Specialists of Georgia, Atlanta, Georgia, United States

🇺🇸

Grene Vision Group, Wichita, Kansas, United States

🇺🇸

Minnesota Eye Consultants, Bloomington, Minnesota, United States

and more 7 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

OMNI® Surgical System Shows Long-Term Efficacy in Comprehensive 22-Study Meta-Analysis for Glaucoma Treatment

Meta-analysis of 22 studies demonstrates significant long-term intraocular pressure reduction and decreased medication dependence using the OMNI® Surgical System for glaucoma treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.